FCGR3A and cancer: In CLDN3-positive cancer cells, h4G3 showed dose-dependent ADCC according to the level of CLDN3 expression through NK-92MI-CD16a cells, and there was no ADCC in CLDN3-negative cancer cells (Figure 4A).